[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100561563":3},{"organization":4,"outcomesModule":7,"designInfo":18,"detailedDescription":11,"studyPopulation":11,"armGroups":24,"interventions":39,"overallOfficials":11,"centralContacts":45,"locations":51,"responsibleParty":88,"collaborators":11,"id":90,"slug":11,"hasResults":91,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":11,"eligibilityCriteria":95,"healthyVolunteers":91,"sex":96,"minAge":97,"maxAge":98,"enrollmentInfo":99,"targetDuration":11,"studyType":102,"phases":103,"briefSummary":106,"conditions":107,"keywords":109,"overallStatus":54,"whyStopped":11,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":123},{"fullName":5,"class":6},"AAVantgarde Bio Srl","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"To measure the number and severity of treatment related adverse events following treatment with AAVB-081",null,"61 months",[14,16],{"measure":15,"description":11,"timeFrame":12},"Change from baseline in microperimetry following treatment with AAVB-081",{"measure":17,"description":11,"timeFrame":12},"Change from baseline in static perimetry following treatment with AAVB-081",{"allocation":19,"interventionModel":20,"interventionModelDescription":11,"primaryPurpose":21,"observationalModel":11,"timePerspective":11,"maskingInfo":22},"NON_RANDOMIZED","SEQUENTIAL","TREATMENT",{"masking":23,"maskingDescription":11,"whoMasked":11},"NONE",[25,31,35],{"label":26,"type":27,"description":28,"interventionNames":29},"Cohort 1","EXPERIMENTAL","AAVB-081 dose level 1",[30],"Biological: AAVB-081",{"label":32,"type":27,"description":33,"interventionNames":34},"Cohort 2","AAVB-081 dose level 2",[30],{"label":36,"type":27,"description":37,"interventionNames":38},"Cohort 3","AAVB-081 dose level 3",[30],[40],{"type":41,"name":42,"description":43,"armGroupLabels":44,"otherNames":11},"BIOLOGICAL","AAVB-081","Single subretinal administration",[26,32,36],[46],{"name":47,"role":48,"phone":49,"phoneExt":11,"email":50},"Clinical Operations Manager","CONTACT","+448000465680","clinicaltrials@aavantgarde.com",[52,67,80],{"facility":53,"status":54,"city":55,"state":11,"zip":11,"country":56,"countryCode":57,"cosmosGeoPoint":58,"geoPoint":63,"contacts":64},"University of Campania Luigi Vanvitelli","RECRUITING","Naples","Italy","IT",{"type":59,"coordinates":60},"Point",[61,62],14.26811,40.85216,{"lat":62,"lon":61},[65],{"name":66,"role":48,"phone":11,"phoneExt":11,"email":11},"Francesca Simonelli",{"facility":68,"status":54,"city":69,"state":11,"zip":11,"country":70,"countryCode":71,"cosmosGeoPoint":72,"geoPoint":76,"contacts":77},"Moorfields Eye Hospital","London","United Kingdom","UK",{"type":59,"coordinates":73},[74,75],-0.12574,51.50853,{"lat":75,"lon":74},[78],{"name":79,"role":48,"phone":11,"phoneExt":11,"email":11},"Michel Michaelides",{"facility":81,"status":54,"city":69,"state":11,"zip":11,"country":70,"countryCode":71,"cosmosGeoPoint":82,"geoPoint":84,"contacts":85},"Retina Clinic London",{"type":59,"coordinates":83},[74,75],{"lat":75,"lon":74},[86],{"name":87,"role":48,"phone":11,"phoneExt":11,"email":11},"Paulo E Stanga",{"type":89,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100561563",false,"NCT06591793","Study of Subretinally Injected AAVB-081 in Patients With Usher Syndrome Type IB (USH1B) Retinitis Pigmentosa","A Phase 1\u002F2 Multicenter, Open-label, Dose Escalation, Safety and Efficacy Study of Subretinal Administration of Dual AAV8.MYO7A, AAVB-081 in Subjects With Usher Syndrome Type IB (USH1B) Retinitis Pigmentosa","Inclusion Criteria:\n\n* Molecular diagnosis of USB1B due to MYO7A mutation\n* Willingness to adhere to protocol per informed consent\n\nExclusion Criteria:\n\n* Unwillingness to meet the requirements of the study\n* Participation in a clinical study with an Investigation Product in the past 6 months\n* Previous participation in another Gene Therapy trial\n* Any condition that would preclude subretinal surgery\n* Complicating ocular and\u002For systemic diseases","ALL","18 Years","50 Years",{"count":100,"type":101},15,"ESTIMATED","INTERVENTIONAL",[104,105],"PHASE1","PHASE2","The purpose of the 081-101 study is to evaluate the safety and tolerability of a single subretinal injection of AAVB-081 in USH1B patients with retinitis pigmentosa due to a mutation in the MYO7A gene. The study will also assess the initial efficacy following AAVB-081 administration.",[108],"Usher Syndrome, Type 1B",[110,111,112,113],"Usher Syndrome","MYO7A","USH1B","Retinitis Pigmentosa","2025-05-01",{"date":116,"type":117},"2025-05-02","ACTUAL",{"date":119,"type":117},"2024-07-02",{"date":121,"type":101},"2029-07",{"name":5,"class":6},3]